Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Sickle-cell disease
David C Rees, Thomas N Williams, Mark T Gladwin
Lancet 2010; 376: 201831
Published Online
December 4, 2010
DOI:10.1016/S01406736(10)61029-X
Department of Paediatric
Haematology, Kings College
Hospital NHS Foundation
Trust, Kings College London,
London, UK (D C Rees FRCP);
Kenya Medical Research
Institute Centre for Geographic
Medicine Research-Coast, Kili,
Kenya (T N Williams PhD);
Nueld Department of Clinical
Medicine, University of Oxford,
Oxford, UK (T N Williams); and
Pulmonary, Allergy and Critical
Care Medicine and Vascular
Medicine Institute, University
of Pittsburgh, Pittsburgh, PA,
USA (Prof M T Gladwell MD)
Correspondence to:
Dr David C Rees, Department of
Paediatric Haematology,
Kings College Hospital NHS
Foundation Trust, Denmark Hill,
Kings College London, London
SE5 9RS, UK
david.rees@kcl.ac.uk
Sickle-cell disease is one of the most common severe monogenic disorders in the world. Haemoglobin polymerisation,
leading to erythrocyte rigidity and vaso-occlusion, is central to the pathophysiology of this disease, although the
importance of chronic anaemia, haemolysis, and vasculopathy has been established. Clinical management is basic
and few treatments have a robust evidence base. One of the main problems of sickle-cell disease in children is the
development of cerebrovascular disease and cognitive impairment, and the role of blood transfusion and
hydroxycarbamide for prevention of these complications is starting to be understood. Recurrent episodes of vasoocclusion and inammation result in progressive damage to most organs, including the brain, kidneys, lungs, bones,
and cardiovascular system, which becomes apparent with increasing age. Most people with sickle-cell disease live in
Africa, where little is known about this disease; however, we do know that the disorder follows a more severe clinical
course in Africa than for the rest of the world and that infectious diseases have a role in causing this increased
severity of sickle-cell disease. More work is needed to develop eective treatments that specically target
pathophysiological changes and clinical complications of sickle-cell disease.
Introduction
Pathophysiology
Classication
The term sickle-cell disease is used to refer to all the
dierent genotypes that cause the characteristic clinical
syndrome, whereas sickle-cell anaemia, the most
common form of sickle-cell disease, refers specically to
homozygosity for the S allele. In this Seminar, we mostly
discuss sickle-cell anaemia, because there is little
evidence for the management of other types of sickle-cell
disease. In populations of African ethnic origin, sicklecell anaemia typically accounts for 70% of cases of sicklecell disease, with most of the remainder having
haemoglobin SC disease (HbSC disease) owing to the coinheritance of the S and C alleles.13 The third major type
of sickle-cell disease occurs when S is inherited with a
-thalassaemia allele, causing HbS/-thalassaemia; this
is a variable disorder dependent on the type of the
-thalassaemia mutation.14 Apart from the many dierent
types of HbS/-thalassaemia, ten further genotypes that
cause sickle-cell disease have been described, although
most are rare (table 2).
2018
Seminar
S
NR
HJB
S
S
10 m
Importance
1910
1924
1924
1948
1948
1951
Characteristics of polymerisation
of deoxygenated HbS7
Primary molecular
mechanism identied
1984
1995
Ecacy of hydroxycarbamide11
Only disease-modifying
drug identied
1998
Seminar
Characteristics
Severe sickle-cell disease
HbS/S (6Glu>Val/6Glu>Val); sickle-cell anaemia
HbS/ thalassaemia
Most prevalent in the eastern Mediterranean region and India; 15% HbA present14
HbS/OArab (6Glu>Val/121Glu>Lys)
Reported in north Africa, the Middle East, and the Balkans; relatively rare14
HbS/C Harlem (6Glu>Val/6Glu>Val/, 73Asp>Asn) Electrophoretically resembles HbSC, but clinically severe; double mutation in -globin gene; very rare15
HbC/S Antilles (6Glu>Lys/6Glu>Val, 23ValIle)
Double mutation in -globin gene results in severe sickle-cell disease when co-inherited with HbC;
very rare16
HbS/Quebec-CHORI (6Glu>Val/87Thr>Ile)
Two cases described; resembles sickle-cell trait with standard analytical techniques17
Dominant form of sickle-cell disease caused by double mutation in -globin gene; very rare18
HbS/E (6Glu>Val/26Glu>Lys)
HbE predominates in southeast Asia and so HbSE uncommon, although frequency is increasing with
population migration19
Dominant form of sickle-cell disease; double mutation results in Hb with low oxygen anity; one
case described20
Group of disorders caused by large deletions of the -globin gene complex; typically 30% fetal
haemoglobin14
HbS/other Hb variants
HbS is co-inherited with many other Hb variants, and symptoms develop only in extreme hypoxia
Genotypes that have been reported to cause sickle-cell disease are listed. All include at least one copy of the S allele, in combination with one or more mutations in the
-globin gene. HbS=sickle haemoglobin. HbA=haemoglobin variant A. HbE=haemoglobin variant E. Hb=haemoglobin.
Epidemiology
The global distribution of HbS is indicative of two
factors: selection for carriers through their survival
advantage in malaria-endemic regions and subsequent
migration. Four region-specic African haplotypes (the
Senegal, Benin, Bantu, and Cameroon haplotypes) and
one Asian haplotype (the Arab-India haplotype) have
been dened, providing support for the hypothesis that
the mutation causing HbS has occurred, and been
locally amplied, on at least two, and possibly several,
separate occasions.49 The evidence that malaria caused
this amplication, which was rst suggested more than
60 years ago,50 is now substantial. In addition to the
close geographic correlation between the frequency of
the HbS gene in populations and the historic incidence
of malaria49 (gure 3), evidence for the partial resistance
of carriers to all forms of Plasmodium falciparum malaria
has been reported in many populations.55,56 Although
the mechanism of this protection is yet to be fully
understood, it probably includes both innate and
immune-mediated mechanisms.57 The genetic defects
that commonly combine with HbS to result in sicklecell disease (HbC and -thalassaemia) have also occurred
through malaria selection,49,57 with the result that such
defects reach their highest frequencies in similar
populations.49 The prevalence of sickle-cell disease is
highest in sub-Saharan Africa. Although the scarcity of
www.thelancet.com Vol 376 December 11, 2010
Seminar
Acute pain
Acute chest syndrome
Hyposplenism
Osteonecrosis
Nephropathy
Deoxygenated erythrocyte with polymerisation of HbS
Reperfusion
Haemolysis
Pulmonary hypertension
Priapism
Leg ulcers
Cerebrovascular disease
NO
Functional NO deciency
Vasculopathy and endothelial dysfunction
Seminar
Eastern Mediterranean
region 6491
European
region 1292
American
region
9047
African
region
233 289
South-East
Asian region
26 037
Western Pacic
region 13
Seminar
Phenotypic heterogeneity
The presentation and clinical course of sickle-cell disease
shows substantial variation. For example, in the
Cooperative Study of Sickle Cell Disease in the USA,68
39% of 3578 patients with sickle-cell anaemia had no
episodes of pain but 1% had more than six per year. Such
variability is characteristic of the disease and many of its
complications, including cerebrovascular disease, acute
chest syndrome, and premature death.
The two best established genetic modiers are
determinants of fetal haemoglobin concentrations and
co-inheritance of -thalassaemia. The maintenance of high
fetal haemoglobin concentrations beyond infancy has long
been recognised to ameliorate many aspects of sickle-cell
disease,6 including predicting increased life expectancy,30
and reducing the frequency of both acute pain68 and leg
ulcers.69 The fetal haemoglobin concentration in patients
with sickle-cell anaemia varies from 1% to 30%, and is
inherited as a quantitative genetic trait. Three major loci
have been identied, which account for up to 50% of this
variation in sickle-cell anaemia: the Xmn1 polymorphism
in the promoter region of the G globin genes,70 the HMIP
locus on chromosome 6q23.3,71 and BCL11A on
chromosome 2.72 Genetic variation at these three loci is
likely to account for some of the clinical diversity seen in
sickle-cell disease, as has already been reported for acute
pain,73 and could be targeted to help to improve prenatal
diagnosis and accuracy of neonatal prognostication.
-thalassaemia trait exists in up to 30% of patients of
African origin with sickle-cell disease,74 and is present in
more than 50% of patients with this disease in India75
and Saudi Arabia.76 -thalassaemia reduces the
concentration of haemoglobin in each erythrocyte,
decreasing the tendency of HbS to polymerise, which
results in increased haemoglobin concentrations and
decreased rates of haemolysis. The clinical eects of
-thalassaemia are variable but generally benecial for
patients, with reduced occurrence of stroke,77 gall stones,78
leg ulcers,74 and priapism,79 although pain frequency is
not reduced.68 Data from some studies indicate an
increased frequency of pain in patients with
-thalassaemia, possibly associated with the increased
haematocrit and blood viscosity.80
Several genetic association studies have been done to
try and link single nucleotide polymorphisms with
particular complications of sickle-cell disease. Some
associations are well described and make biological
sense, such as the link between UGT1A promoter
polymorphisms and gall stones.78 Most studies have
investigated large-vessel stroke, and two independent
studies have suggested an association with the tumour
necrosis factor promoter polymorphism at position
www.thelancet.com Vol 376 December 11, 2010
General management
Diagnosis and screening
Diagnosis of sickle-cell disease is based on analysis of
haemoglobin. Typically, this analysis involves protein
electrophoresis or chromatography, which are cheap
techniques and widely available worldwide, although
haemoglobin mass spectrometry and DNA analysis are
being increasingly used because these techniques enable
high-throughput testing.89 Antenatal screening is
available to women in some countries to help to identify
couples who are at risk of having a baby with sickle-cell
disease, and to oer prenatal diagnosis.89 Universal
neonatal screening programmes are established in the
USA and England, with other programmes being
developed in Europe and Africa.67 Some of the
improvement in survival in sickle-cell disease over the
past few decades has been attributed to neonatal
screening, facilitating early access to prophylaxis with
penicillin, comprehensive care, and parental education
on the early detection of complications such as acute
splenic sequestration (panel 1).90
Hydroxycarbamide
Many cytotoxic drugs increase fetal haemoglobin
concentrations, which is potentially benecial in patients
with sickle-cell disease. Hydroxycarbamide was chosen for
studies of sickle-cell disease because of its oral ecacy and
low toxic eects,91 although other benecial eects have
subsequently emerged, including increasing haemoglobin
concentrations, decreasing platelet and white cell counts,
changing expression of adhesion molecules,92 and nitric
oxide generation.93 In a randomised controlled trial,11
hydroxycarbamide decreased the frequency of painful
episodes, acute chest syndrome, the need for blood
transfusion, and admission to hospital in patients with
sickle-cell anaemia. Many subsequent studies have shown
evidence of similar benet in both adults and children.94,95
Hydroxycarbamide is well tolerated, with dose-dependent
2023
Seminar
2024
Seminar
Infection
Bacterial infections are a major cause of morbidity and
mortality in children with sickle-cell disease. The
increased susceptibility of aected children is likely to
result from several causes, including impaired splenic
function, defects in complement activation, micronutrient
deciencies, and tissue ischaemia.14 Several organisms,
including S pneumoniae, H inuenza, and non-typhi
Salmonella species, have been identied as important
causes of infection in developed countries,14 where
substantial improvements in prognosis have followed the
introduction of penicillin prophylaxis and immunisation
with conjugate vaccines directed against S pneumoniae
and H inuenzae type b.8,9,122 Similar organisms are
probably involved in most of the infections in patients in
sub-Saharan Africa,61 although data are less clear.58
Neurological complications
Sickle-cell anaemia is one of the most common causes
of stroke in children. Most cases are associated with
vasculopathy aecting the distal internal carotid and
middle cerebral arteries, although extracranial vasculopathy can also be present.123 Although the mechanisms
for stroke remain uncertain, contributory factors to this
vasculopathy include anaemia, leucocytois, hypoxaemia,
abnormal rheology causing endothelial damage,
functional nitric oxide deciency associated with
haemolysis,77,124 and impaired regulation of blood ow
causing hyperaemia.125,126 The vasculopathy seems to
start in infancy, with a rst-stroke incidence of 102 per
100 patient-years between the ages of 2 years and 5 years,
and 11% of patients with sickle-cell disease have had a
stroke by the age of 20 years.32 Vasculopathy can be
detected at an early stage by use of transcranial doppler
scanning. In the Stroke Prevention in Sickle Cell
Anemia (STOP) study,12 regular blood transfusion to
keep HbS below 30% reduced the risk of stroke by 90%
in patients with increased transcranial doppler velocities.
A programme of transcranial doppler screening has
been established in some countries, with evidence of a
decrease in stroke incidence.127 Studies are investigating the role of hydroxycarbamide in the prevention
of cerebrovascular disease.100 In the Stroke with
Transfusions Changing to Hydroxyurea (SWiTCH)
2025
Seminar
Regional
hypoxia
Erythrocyte
rigidity
Decreased
oxygen delivery
Desaturated
haemoglobin
41 integrin
VCAM-1
Shunting of
blood from veins
to arteries
Increased endothelial
VCAM-1 expression and adhesion
Fat embolism
Microvasculature occlusion
and bone marrow infarction
NO
Increased erythrocyte adhesion
in lung-pulmonary infarction
Inammation:
secretory
phospholipase A2
NO
Hypoventilation
and atelectasis
secondary to rib
and vertebral
infarction
Acute chest syndrome
Pulmonary infection*
2026
Seminar
Pulmonary hypertension
Pulmonary hypertension is an increasingly recognised
complication of sickle-cell disease in teenagers and adults.
In three prospective studies in adults,33,36,37 in which
echocardiography was used to measure tricuspid
regurgitant jet velocity, 20% of the participants had mild
elevation in estimated pulmonary artery pressures, dened
by a pulmonary artery systolic pressure greater than 35 mm
Hg (upper limit of normal is 32 mm Hg), and 9% had
moderate-to-severe pulmonary hypertension (>45 mm
Hg). Despite increases in pulmonary pressure that are
much lower than those observed in patients with idiopathic
or hereditable pulmonary hypertension, the prospective
risk of death associated with even mild pulmonary
hypertension is high in patients with sickle-cell disease.33,36,37
In a French study,138 despite the exclusion of patients with
low creatinine clearance, reduced lung capacity, and
liver diseaseall additional major risk factors for
the development of pulmonary hypertension6% of
385 patients had a mean pulmonary artery pressure of
greater than 25 mm Hg at right heart catheterisation.
Although this prevalence is lower than in studies using
echocardiography, the occurrence of pulmonary
hypertension is high compared with other diseases
associated with its development, and all deaths occurred in
those with pulmonary hypertension.138
We are not aware of any robust evidence about how best
to treat pulmonary hypertension in patients with sickle-cell
disease. Risk factors such as hypoxaemia, sleep apnoea,
pulmonary thromboembolic disease, restrictive lung
disease, left ventricular systolic and diastolic dysfunction,
severe anaemia, and iron overload need to be identied
and treated. Treatment options include hydroxycarbamide,
with regular blood transfusions if there is no response.134
In patients with severe pulmonary hypertension (tricuspid
Therapeutic approach
Specic examples
To improve rheology
Poloxamer-188, bosentan
To reduce inammation
Dexamethasone, varespladib
To increase fetal haemoglobin production Treat with cytotoxic drugs, short-chain fatty acids,
immunomodulatory drugs
Heparin, sulfasalazine
Decitabine, butyrate, pomalidomide, lenalidomide
Empirical use
Nix-0699
2027
Seminar
Heart disease
Left-sided heart disease occurs in about 13% of adults with
sickle-cell disease and is mainly caused by diastolic
dysfunction; systolic dysfunction can also occur and
valvular disease is present in about 2% of patients.33 The
presence of diastolic dysfunction alone in patients with
sickle-cell disease is an independent risk factor for
mortality.140 Patients with both pulmonary vascular disease
and diastolic dysfunction are at a particularly high risk of
death (odds ratio for death 120, 95% CI 38381,
p<0001).140 Pulmonary pressures rise acutely during vasoocclusive pain and even more during acute chest
syndrome. In a study,141 13% of patients manifested right
heart failure with acute chest syndrome, and this subgroup
had the highest risk of mechanical ventilation and death.
Renal complications
Renal damage is almost inevitable in sickle-cell disease.
There is a strong tendency for HbS to polymerise in the
renal medulla, because of the low partial pressure of
oxygen, the low pH, and the high osmolality causing
erythrocyte dehydration. The consequent vaso-occlusion
causes renal infarction with papillary necrosis, and
medullary brosis with focal segmental glomerulosclerosis. Glomerular hyperltration and tubular
dysfunction also occur, and are possibly associated with
anaemia and increased sensitivity to prostaglandins.142
Renal dysfunction is apparent from an early age in
patients with sickle-cell anaemia, with glomerular
hyperltration apparent at 13 months.143 Microalbuminuria is common in childhood and up to 20% of
adults develop nephrotic-range protein loss, with more
than 35 g proteinuria in 24 h.142 30% of adults develop
chronic renal failure, which is a contributory factor in
many deaths.30 Other renal manifestations include
haematuria, renal medullary carcinoma, and nocturnal
enuresis.142 Treatment is beginning to focus on the early
use of hydroxycarbamide and angiotensin-converting
enzyme inhibitors in children with clinically signicant
albuminuria,102 although there is little supportive evidence
at present. In end-stage kidney failure, 10-year survival
2028
Future developments
Stem-cell transplantation and gene therapy seem likely to
become more widely applicable as new techniques
develop, with the use of induced pluripotent stem cells
oering the most promise.112 Data from genetic
association studies should help to identify more unlinked
and epigenetic factors to explain phenotypic diversity and
to enable better prognosis, which might lead to the
treatment of specic complications. Many drugs have
given in-vitro or early benet in sickle-cell disease without
becoming clinically useful, and table 3 lists some
promising pharmaceutical approaches in development.
Improved understanding of sickle-cell disease in Africa
would benet the largest number of patients, and could
facilitate improved management of patients worldwide,
including Europe and the USA.
Contributors
All authors contributed to the writing and editing of all sections of the
Seminar. MTG was mainly responsible for the sections on
pathophysiology and cardiopulmonary complications; TNW for the
sections on epidemiology, infection, and Africa; and DCR for the rest.
Conicts of interest
DCR has received consultancy fees from Sangart and speakers fees and
travel expenses from Novartis; he is chief investigator for the UK for a
clinical trial of conjugated pneumococcal vaccine sponsored by Wyeth,
and receives research funding from the UK Medical Research Council.
TNW is supported by the Wellcome Trust, UK (grant 076934) and the
European Virtual Institute for Malaria Research. MTG receives grant
support from the Institute for Transfusion Medicine, the Hemophilia
Center of Western Pennsylvania, PA, USA; and federal funding from the
National Heart, Lung and Blood Institute, National Institute of Diabetes
and Digestive and Kidney Diseases, and National Institute of Arthritis and
Musculoskeletal and Skin Diseases of the National Institutes of Health
(grants R01HL098032, RC1DK085852, and P30AR058910). He has
received money for grants or grants pending from the US Government.
His institution has received money grants or grants pending from the
National Institutes of Health, the US Government, and INO Therapeutics.
Acknowledgments
We thank Frederic Piel of the Malaria Atlas Project (University of Oxford,
Oxford, UK) for producing gure 3, and Vidhya Murthy and
Robin Ireland (Department of Haematological Medicine, Kings College
Hospital, London, UK) for gure 1.
References
1
Weatherall D, Hofman K, Rodgers G, Run J, Hrynkow S. A case
for developing North-South partnerships for research in sickle cell
disease. Blood 2005; 105: 92123.
2
Herrick JB. Peculiar elongated and sickle-shaped red blood
corpuscles in a case of severe anemia. Arch Intern Med 1910;
6: 51721.
3
Sydenstricker VP. Further observations on sickle cell anemia.
J Am Med Ass 1924; 83: 1215.
4
Graham GS. Case of sickle cell anaemia with necropsy.
Arch Intern Med 1924; 34: 778800.
5
Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia,
a molecular disease. Science 1949; 110: 54348.
6
Watson J, Staham AW, Billelo FP. The signicance of the paucity
of sickle cells in newborn negro infants. Am J Med Sci 1948;
215: 41923.
Seminar
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
Perutz MF, Liquori AM, Eirich F. X-ray and solubility studies of the
haemoglobin of sickle-cell anaemia patients. Nature 1951; 167: 92931.
John AB, Ramlal A, Jackson H, Maude GH, Sharma AW,
Serjeant GR. Prevention of pneumococcal infection in children
with homozygous sickle cell disease. BMJ 1984; 26: 156770.
Gaston MH, Verter JL, Woods G, et al. Prophylaxis with oral penicillin
in children with sickle cell anemia. N Engl J Med 1986; 314: 159399.
Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L,
Billings FT 3rd. Bone-marrow transplantation in a patient with
sickle-cell anemia. N Engl J Med 1984; 311: 78083.
Charache S, Terrin ML, Moore RD, et al. Eect of hydroxyurea on
frequency of painful crises in sickle cell anemia. N Engl J Med 1995;
332: 131722.
Adams RJ, McKie VC, Hsu L, et al. Prevention of a rst stroke by
transfusions in children with sickle cell anemia and abnormal
results on transcranial Doppler ultrasonography. N Engl J Med 1998;
339: 511.
Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC
disease. Blood Rev 2003; 17: 16778.
Serjeant GR, Serjeant BE. Sickle cell disease. Oxford, UK. Oxford
University Press, 2001.
Moo-Penn W, Bechtel K, Jue D, et al. The presence of hemoglobin S
and C Harlem in an individual in the United States. Blood 1975;
46: 36367.
Monplaisir N, Merault G, Poyart C, et al. Hemoglobin S Antilles:
a variant with lower solubility than hemoglobin S and producing
sickle cell disease in heterozygotes. Proc Natl Acad Sci USA 1986;
83: 936367.
Witkowska HE, Lubin BH, Beuzard Y, et al. Sickle cell disease in
a patient with sickle cell trait and compound heterozygosity for
hemoglobin S and hemoglobin Quebec-Chori. N Engl J Med 1991;
325: 115054.
Nagel RL, Daar S, Romero JR, et al. HbS-Oman heterozygote: a new
dominant sickle syndrome. Blood 1998; 92: 437582.
Masiello D, Heeney MM, Adewoye AH, et al. Hemoglobin SE
diseasea concise review. Am J Haematol 2007; 82: 64349.
Geva A, Clark JJ, Zhang Y, Popowicz A, Manning JM, Neufeld EJ.
Hemoglobin Jamaica Plaina sickling hemoglobin with reduced
oxygen anity. N Engl J Med 2004; 351: 153238.
Bunn HF. Pathogenesis and treatment of sickle cell disease.
N Engl J Med 1997; 337: 76269.
Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S
polymerization: primary determinant of the hemolytic and clinical
severity of the sickling syndromes. Blood 1985; 65: 18389.
Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal
hemoglobin necessary for treatment of sickle cell disease.
N Engl J Med 1988; 318: 9699.
Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular
paradigm. Curr Opin Hematol 2002; 9: 10106.
Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary
role for adherent leukocytes in sickle cell vascular occlusion: a new
paradigm. Proc Natl Acad Sci USA 2002; 99: 304751.
Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have
vascular inammation. Blood 2003; 101: 395359.
Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM,
Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle
transgenic mice. Blood 2000; 96: 31420.
Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH
oxidase mediates the cerebral microvascular dysfunction in sickle
cell transgenic mice. Faseb J 2005; 19: 98991.
Belcher JD, Mahaseth H, Welch TE, et al. Critical role of endothelial
cell activation in hypoxia-induced vasoocclusion in transgenic sickle
mice. Am J Physiol Heart Circ Physiol 2005; 288: H271525.
Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell
disease. Life expectancy and risk factors for early death.
N Engl J Med 1994; 330: 163944.
Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of
blood pressure in sickle cell disease: risks for stroke and death
associated with relative hypertension in sickle cell anemia.
Am J Med 1997; 102: 17177.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular
accidents in sickle cell disease: rates and risk factors. Blood 1998;
91: 28894.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
2029
Seminar
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
2030
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
Seminar
106 Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial
iron loading in transfusion-dependent thalassemia and sickle cell
disease. Blood 2004; 103: 193436.
107 Vichinsky E, Onyekwere O, Porter JB, et al. A randomised
comparison of deferasirox versus deferoxamine for the treatment of
transfusional iron overload in sickle cell disease. Br J Haematol
2007; 136: 50108.
108 Bhatia M, Walters MC. Hematopoietic cell transplantation for
thalassaemia and sickle cell disease: past, present and future.
Bone Marrow Transplant 2008; 41: 10917.
109 Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic
stem-cell transplantation for sickle cell disease. N Engl J Med 2009;
361: 230917.
110 Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell
disease in transgenic mouse models by gene therapy. Science 2001;
294: 236871.
111 Persons DA. Hematopoietic stem cell gene transfer
for the treatment of hemoglobin disorders.
Hematology Am Soc Hematol Educ Program 2009; 69097.
112 Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell
anemia mouse model with iPS cells generated from autologous
skin. Science 2007; 318: 192023.
113 Field JJ, Macklin EA, Yan Y, Strunk RC, DeBaun MR. Sibling
history of asthma is a risk factor for pain in children with sickle cell
anemia. Am J Hematol 2008; 83: 85557.
114 Hargrave DR, Wade A, Evans JP, Hewes DK, Kirkham FJ. Nocturnal
oxygen saturation and painful sickle cell crises in children.
Blood 2003; 101: 84648.
115 Bartolucci P, El Murr T, Roudot-Thoraval F, et al. A randomized,
controlled clinical trial of ketoprofen for sickle-cell disease
vaso-occlusive crises in adults. Blood 2009; 114: 374247.
116 Jacobson SJ, Kopecky BA, Joshi P, Babul N. Randomized trial of
oral morphine for painful episodes of sickle-cell disease in children.
Lancet 1997; 350: 135861.
117 National Condential Enquiry into Patient Outcome and Death.
A sickle crisis? A report of the National Condential Enquiry Into
Patient Outcome And Death (2008). http://www.ncepod.org.
uk/2008report1/Downloads/Sickle_report.pdf (accessed Jan 4, 2010).
118 Grin TC, McIntire D, Buchanan GR. High-dose intravenous
methylprednisolone therapy for pain in children and adolescents
with sickle cell disease. N Engl J Med 1994; 330: 73337.
119 Orringer EP, Casella JF, Ataga KI, et al. Puried poloxamer 188 for
treatment of acute vaso-occlusive crisis of sickle cell disease:
a randomized controlled trial. JAMA 2001; 286: 2099106.
120 Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA,
Brugnara C. Preliminary assessment of inhaled nitric oxide for
acute vaso-occlusive crisis in pediatric patients with sickle cell
disease. JAMA 2003; 289: 113642.
121 Anon. Inhaled nitric oxide for pediatric painful sickle crisis. Aug 27,
2009. http://clinicaltrials.gov/ct2/show/NCT00142051 (accessed
Aug 17, 2010).
122 Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive
pneumococcal disease among individuals with sickle cell disease
before and after the introduction of the pneumococcal conjugate
vaccine. Clin Infect Dis 2007; 44: 142833.
123 Deane CR, Goss D, Bartram J, et al. Extracranial internal carotid
arterial disease in children with sickle cell anaemia. Haematologica
2010; 95: 128792.
124 ODriscoll S, Height SE, Dick MC, Rees DC. Serum lactate
dehydrogenase as a biomarker in children with sickle cell disease.
Br J Haematol 2008; 140: 20609.
125 Switzer JA, Hess DC, Nichols FT, Adams RJ. Pathophysiology and
treatment of stroke in sickle-cell disease: present and future.
Lancet Neurol 2006; 5: 50112.
126 Prohovnik I, Hurlet-Jensen A, Adams R, De Vivo D, Pavlakis SG.
Hemodynamic etiology of elevated ow velocity and stroke in
sickle-cell disease. J Cereb Blood Flow Metab 2009; 29: 80310.
127 Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke
rates in Californian children with sickle cell disease. Blood 2004;
104: 36339.
128 Anon. Stroke With Transfusions Changing to Hydroxyurea
(SWiTCH). June 25, 2010. http://clinicaltrials.gov/ct2/show/
NCT00122980 (accessed Aug 17, 2010).
129 Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009;
114: 511725.
130 Smith ER, McClain CD, Heeney M, Scott RM. Pial synangiosis in
patients with moyamoya syndrome and sickle cell anemia:
perioperative management and surgical outcome.
Neurosurg Focus 2009; 26: 18.
131 Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts
in young children with sickle cell disease. Br J Haematol 2009;
146: 30005.
132 Anon. Silent cerebral infarct multi-center clinical trial. May 6, 2010.
http://clinicaltrials.gov/ct2/show/NCT00072761
(accessed Aug 17, 2010).
133 Hogan AM, Pit-ten Cate IM, Vargha-Khadem F, Prengler M,
Kirkham FJ. Physiological correlates of intellectual function in
children with sickle cell disease: hypoxaemia, hyperaemia and
brain infarction. Dev Sci 2006; 9: 37987.
134 Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell
disease. N Engl J Med 2008; 359: 225465.
135 Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes
of the acute chest syndrome in sickle cell disease. N Engl J Med
2000; 342: 185565.
136 Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT,
Buchanan GR. Benecial eect of intravenous dexamethasone in
children with mild to moderately severe acute chest syndrome
complicating sickle cell disease. Blood 1998; 92: 308289.
137 Machado RF, Gladwin MT. Pulmonary Complications of
Hematological Disease. In: Murray RJ, Broaddus VC, Martin T,
et al. Murray and Nadels Textbook of Respiratory Medicine,
5th edn. Philadelphia, PA: Elsevier, 2010: 19992021.
138 Bachir D, Parent F, Hajji L, et al. Prospective multicentric survey on
pulmonary hypertension (PH) in adults with sickle cell disease.
Blood 2009; 114: 572.
139 Machado RF, Martyr S, Kato GJ, et al. Sildenal therapy in patients
with sickle cell disease and pulmonary hypertension. Br J Haematol
2005; 130: 44553.
140 Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is
an independent risk factor for death in patients with sickle cell
disease. J Am Coll Cardiol 2007; 49: 47279.
141 Mekontso Dessap A, Leon R, Habibi A, et al. Pulmonary
hypertension and cor pulmonale during severe acute chest
syndrome in sickle cell disease. Am J Respir Crit Care Med 2008;
177: 64653.
142 Scheinman JI. Sickle cell disease and the kidney.
Nat Clin Pract Nephrol 2009; 5: 7888.
143 Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with
sickle cell anemia: baseline data from the BABY HUG trial.
J Pediatr 2010; 156: 6670.
144 Neumayr LD, Aguilar C, Earles AN, et al. Physical therapy alone
compared with core decompression and physical therapy for
femoral head osteonecrosis in sickle cell disease. Results of a
multicenter study at a mean of three years after treatment.
J Bone Joint Surg Am 2006; 88: 257382.
145 Hernigou P, Daltro G, Filippini P, Mukasa MM, Manicom O.
Percutaneous implantation of autologous bone marrow
osteoprogenitor cells as treatment of bone avascular necrosis related
to sickle cell disease. Open Orthop J 2008; 2: 6265.
146 Sayag D, Binaghi M, Souied EH, et al. Retinal photocoagulation for
proliferative sickle cell retinopathy: a prospective clinical trial with
new sea fan classication. Eur J Ophthalmol 2008; 18: 24854.
147 Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal
bevacizumab (Avastin) injection associated with regression of
retinal neovascularization caused by sickle cell retinopathy.
Acta Ophthalmol Scand 2006; 84: 83435.
148 Mekeel KL, Langham MR Jr, Gonzalez-Peralta R, Fujita S,
Hemming AW. Liver transplantation in children with sickle-cell
disease. Liver Transpl 2007; 13: 50508.
149 Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ.
Treatment of recurrent priapism in sickle cell anemia with
nasteride: a new approach. Urology 2009; 74: 105457.
150 Hagar W, Vichinsky E. Advances in clinical research in sickle cell
disease. Br J Haematol 2008; 141: 34656.
2031